Wang Hui, Zhou Jing, Sun Caoyu, Dong Xu
Department of Ophthalmology, The 4th People's Hospital of Shenyang, Shenyang, Liaoning 110031, China.
Evid Based Complement Alternat Med. 2021 Feb 3;2021:9357108. doi: 10.1155/2021/9357108. eCollection 2021.
To evaluate the efficacy and safety of intravitreal conbercept (IVC) for diabetic retinopathy (DR) compared with intravitreal triamcinolone acetonide (IVTA). PubMed, Embase, Cochrane Library, China National Knowledge Infrastructure, VIP database, and Wanfang database were searched from their earliest records to January 2020. We included randomized controlled trials (RCTs) evaluating the efficacy and safety of conbercept in DR patients compared with ITVA. Outcomes included the mean changes from the baseline in best corrected visual acuity (BCVA) score, central macular thickness (CMT), quality of life (QoL) over time, and the incidence of adverse events (AEs). A total of 19 RCTs involving 1,811 eyes were included in this meta-analysis. IVC might improve BCVA (WMD = 0.10, 95% CI (0.07, 0.12), < 0.001) and reduce CMT (WMD = -102.5, 95% CI (-148.48, -56.53), < 0.001) compared to IVTA. The incidence of AEs in patients receiving IVC was significantly lower than those receiving IVTA (RR = 0.29, 95% CI (0.21, 0.40), < 0.001). Patients with IVC treatments acquired better self-care, mobility, social, and mental scores compared with IVTA ( < 0.001). Current evidence shows that IVC has better effects and safety than IVTA in treating DR, and it can significantly enhance the QoL of patients with DR.
为评估玻璃体内注射康柏西普（IVC）与玻璃体内注射曲安奈德（IVTA）治疗糖尿病性视网膜病变（DR）的疗效和安全性。检索了PubMed、Embase、Cochrane图书馆、中国知网、维普数据库和万方数据库，检索时间从各数据库最早记录至2020年1月。我们纳入了评估康柏西普与IVTA相比治疗DR患者的疗效和安全性的随机对照试验（RCT）。结局指标包括最佳矫正视力（BCVA）评分、中心黄斑厚度（CMT）随时间的平均变化、生活质量（QoL）以及不良事件（AE）的发生率。本荟萃分析共纳入19项涉及1811只眼的RCT。与IVTA相比，IVC可能改善BCVA（加权均数差[WMD]=0.10，95%可信区间[CI]（0.07，0.12），P<0.001）并降低CMT（WMD=-102.5，95%CI（-148.48，-56.53），P<0.001）。接受IVC治疗的患者AE发生率显著低于接受IVTA治疗的患者（风险比[RR]=0.29，95%CI（0.21，0.40），P<0.001）。与IVTA相比，接受IVC治疗的患者在自我护理、活动能力、社交和心理评分方面更高（P<0.001）。当前证据表明，IVC在治疗DR方面比IVTA具有更好的效果和安全性，并且可以显著提高DR患者的生活质量。
